A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
Crossref DOI link: https://doi.org/10.2337/dc15-0165
Published Online: 2015-09-10
Published Print: 2016-02-01
Update policy: https://doi.org/10.2337/ada-journal-policies
Nauck, Michael A.
Petrie, John R.
Sesti, Giorgio
Mannucci, Edoardo
Courrèges, Jean-Pierre
Lindegaard, Marie L.
Jensen, Christine B.
Atkin, Stephen L.
